{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T10:47:34Z","timestamp":1750330054060,"version":"3.40.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.numecd.2024.03.007","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T09:48:41Z","timestamp":1710150521000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5548-8878","authenticated-orcid":false,"given":"Sarah B.","family":"Pohl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Engelbertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Reinecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser M.","family":"Malyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Meyborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1557-8097","authenticated-orcid":false,"given":"Tobias J.","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7206-3719","authenticated-orcid":false,"given":"Julian","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9439","authenticated-orcid":false,"given":"Katrin","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"40","key":"10.1016\/j.numecd.2024.03.007_bib1","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/eurheartj\/ehv428","article-title":"Cardiovascular disease in Europe 2015: epidemiological update","volume":"36","author":"Townsend","year":"2015","journal-title":"Eur Heart J"},{"issue":"39","key":"10.1016\/j.numecd.2024.03.007_bib2","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.numecd.2024.03.007_bib3","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","article-title":"Genetic risk, adherence to a healthy lifestyle, and coronary disease","volume":"375","author":"Khera","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.numecd.2024.03.007_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"39","key":"10.1016\/j.numecd.2024.03.007_bib5","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.03.007_bib6","first-page":"1350","article-title":"Lipid lowering therapy in primary and secondary prevention across Europe: are LDL-C goals achieved in Germany? Results from the DA VINCI study","volume":"110","author":"Gouni-Berthold","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.numecd.2024.03.007_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"issue":"9753","key":"10.1016\/j.numecd.2024.03.007_bib8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2024.03.007_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0167-5273(15)31026-3","article-title":"Global burden of CVD: focus on secondary prevention of cardiovascular disease","volume":"201","author":"Bansilal","year":"2015","journal-title":"Int J Cardiol"},{"issue":"34","key":"10.1016\/j.numecd.2024.03.007_bib10","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC national cardiac societies; ESC scientific document group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.numecd.2024.03.007_bib11","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/CIRCULATIONAHA.109.865600","article-title":"German Epidemiological Trial on Ankle Brachial Index Study Group. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease","volume":"120","author":"Diehm","year":"2009","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.numecd.2024.03.007_bib12","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.3390\/jcm11226838","article-title":"Secondary prevention in lower extremity artery disease patients: lipid-lowering therapy and long-term guideline adherence","volume":"11","author":"Mueller","year":"2022","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.numecd.2024.03.007_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1177\/2047487320914115","article-title":"Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: a population-level observational cohort study","volume":"28","author":"Harris","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.numecd.2024.03.007_bib14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2024.03.007_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER)","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am J Cardiol"},{"issue":"25","key":"10.1016\/j.numecd.2024.03.007_bib16","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"IMPROVE-IT investigators. Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.numecd.2024.03.007_bib17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"10349","key":"10.1016\/j.numecd.2024.03.007_bib18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.numecd.2024.03.007_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043714","article-title":"Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients","volume":"11","author":"Davis","year":"2021","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.numecd.2024.03.007_bib20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.03.007_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00392-020-01740-8","article-title":"Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin\/ezetimibe compared to separate pill combination on LDL-C","volume":"111","author":"Katzmann","year":"2022","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"10.1016\/j.numecd.2024.03.007_bib22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"SECURE investigators. Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2024.03.007_bib23","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcsm.12960","article-title":"International Lipid Expert Panel (ILEP). Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"22","key":"10.1016\/j.numecd.2024.03.007_bib24","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or No treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.numecd.2024.03.007_bib25","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and No treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10355","key":"10.1016\/j.numecd.2024.03.007_bib26","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.numecd.2024.03.007_bib27","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.03.007_bib28","first-page":"1695","article-title":"Retrospective longitudinal analysis of prescription data to investigate real world adherence and persistence to lipid-lowering therapy in Germany","volume":"110","author":"Koenig","year":"2021","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"10.1016\/j.numecd.2024.03.007_bib29","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.numecd.2024.03.007_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/10400435.2018.1493710","article-title":"Effects of a long-term smartphone-based self-monitoring intervention in patients with lipid metabolism disorders","volume":"32","author":"Steinert","year":"2020","journal-title":"Assist Technol"},{"issue":"12","key":"10.1016\/j.numecd.2024.03.007_bib31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jama.2015.10945","article-title":"Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease A randomized clinical trial original investigation","volume":"314","author":"Chow","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.numecd.2024.03.007_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/2047487318781109","article-title":"Effects of an intensive long-term prevention programme after myocardial infarction \u2013 a randomized trial","volume":"26","author":"Wienbergen","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.numecd.2024.03.007_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5554","article-title":"Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with Atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe","volume":"1","author":"Khunti","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.numecd.2024.03.007_bib35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324001091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324001091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T18:57:23Z","timestamp":1715108243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475324001091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":34,"alternative-id":["S0939475324001091"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2024.03.007","relation":{},"ISSN":["0939-4753"],"issn-type":[{"type":"print","value":"0939-4753"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2024.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}]}}